|
See related Buminate 25% inj information |
|
|
|
Manufacturer |
Baxter Healthcare |
|
Distributor |
Hong Kong: United Italian/Macau: Firma Chun Cheong |
|
Contents |
Human albumin |
|
Indications |
Hypovolemia, hypoalbuminaemia, burns, adult resp distress syndrome, nephrosis, cardiopulmonary bypass surgery, haemolytic disease of the newborn. |
|
Dosage |
Individualised dosage. Hypovolemic shock Adult Initially 100-200 mL. Childn 2.5-5 mL/kg. May be repeated after 15-30 min. Hypoalbuminaemia Max: 2 g albumin/kg/day. Haemolytic disease of the newborn 1 g/kg prior to or during exchange transfusion. |
|
Contraindications |
Severe heart failure; marked exsiccosis; severe anemia. |
|
Special Precautions |
Low cardiac reserve; marked dehydration. |
|
Adverse Drug Reactions |
Circulatory overload, pulmonary oedema. Rarely, urticaria, chills, fever.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
B05AA01 - albumin ; Belongs to the class of blood substitutes and plasma protein fractions. Used as blood substitutes. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Buminate 25% injection |
|
Buminate 25% 25 g/100 mL x 50 mL |
|
|
|
Manufacturer: |
Baxter Healthcare |
|
Distributor: |
Hong Kong: United Italian
Macau: Firma Chun Cheong
|
|
|
|
